Traditional heart disease evaluation methods, such as a coronary angiogram, can be invasive - a catheter is threaded through the arm or leg to reach the heart, where it injects dye into its arteries so X-ray images can capture how blood flows through the vessels.

Though serious complications from the procedure are rare, they potentially include injury to the artery, an allergic reaction or kidney damage from the dye, as well as heart attack or stroke. This is a problem that Cleerly is trying to solve by measuring this plaque through AI-powered imaging which analyzes non-invasive coronary CT scans.

The company was founded by the respected cardiologist and radiologist James Min in 2017 and spent its early years developing and refining its tech. However, it recently secured major financial backing, which coincides with CTA imaging’s growing status as a priority measure for patients with suspected heart problems. This is set to propel Cleerly into a period of rapid growth as it looks to keep refining its software to attract and keep new customers in the healthcare industry.